Amias

How to order Amias

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Amias on Prescriptsy

Amias is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

What is Amias?

Amias is the UK brand name for candesartan cilexetil , a medicine belonging to the angiotensin II receptor blocker (ARB) class.

It is licensed for the treatment of essential hypertension (high blood pressure) in adults and children aged 6 to 17 years, and for the treatment of heart failure with reduced systolic function when ACE inhibitors are not tolerated.

Amias is manufactured by Takeda and is available as a prescription-only medicine (POM) in the United Kingdom.

Hypertension affects approximately one in three adults in the UK and is one of the most important modifiable risk factors for cardiovascular disease, stroke, kidney disease, and vascular dementia.

Effective blood pressure control reduces the risk of these serious complications, and ARBs like Amias are a well-established treatment option within the NICE hypertension pathway.

Active ingredient and pharmacology

Candesartan cilexetil is a prodrug that is rapidly converted to the active compound, candesartan, during absorption from the gastrointestinal tract.

Candesartan selectively blocks the angiotensin II type 1 (AT1) receptor. Angiotensin II is a potent vasoconstrictor produced by the renin-angiotensin-aldosterone system (RAAS).

By blocking the AT1 receptor, candesartan prevents the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, reduced sodium and water retention, and a lowering of blood pressure.

Unlike ACE inhibitors, ARBs do not inhibit the breakdown of bradykinin.

This explains why the dry cough that commonly occurs with ACE inhibitors is much less frequent with ARBs like Amias.

For this reason, candesartan is often prescribed as an alternative for patients who develop a persistent cough on ramipril, lisinopril, or other ACE inhibitors.

Licensed indications

• Essential hypertension, first-line or alternative antihypertensive treatment in adults and children aged 6 to 17 years.
• Heart failure, treatment of heart failure with reduced left ventricular systolic function (LVEF 40% or below) when ACE inhibitors are not tolerated, or as add-on therapy when symptoms persist despite optimal ACE inhibitor and beta-blocker treatment.

Amias in the NICE hypertension pathway

NICE guideline NG136 (Hypertension in adults) provides a stepwise approach to blood pressure management. For most patients, the first-line treatment choice depends on age and ethnicity:

• Under 55 years, or any age with type 2 diabetes: ACE inhibitor or ARB as first-line treatment.
• 55 years and over, or of Black African or Caribbean family origin: calcium channel blocker as first-line treatment.

Amias can therefore be used as a first-line antihypertensive in younger patients or those with diabetes, or as an alternative to an ACE inhibitor at any age if cough or other ACE inhibitor intolerance occurs.

At step 2, an ARB may be combined with a calcium channel blocker.

At step 3, a combination of ACE inhibitor or ARB, calcium channel blocker, and thiazide-like diuretic is recommended.

Amias vs. other ARBs

Several ARBs are available in the UK, including losartan, valsartan, irbesartan, telmisartan, and olmesartan. They share the same mechanism of action but differ in potency, duration of action, and specific clinical evidence:

• Candesartan (Amias): potent and long-acting. Well-established evidence in hypertension and heart failure (CHARM programme).
• Losartan: the first ARB, with specific evidence in diabetic nephropathy and stroke prevention. Has a mild uricosuric effect, which may be beneficial in patients with gout.
• Valsartan: extensive heart failure evidence (Val-HeFT, VALIANT trials).

In my experience, the choice between ARBs is often guided by local formulary recommendations, patient response, and the specific clinical context.

Candesartan has the advantage of a once-daily dosing regimen, a relatively flat dose-response curve, and strong evidence across both hypertension and heart failure.

Heart failure treatment with Amias

The CHARM programme (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) was a landmark series of clinical trials that established candesartan's role in heart failure management.

The programme demonstrated that candesartan reduced cardiovascular death and heart failure hospitalisations in patients with reduced ejection fraction, both as an alternative to ACE inhibitors (CHARM-Alternative) and as add-on therapy (CHARM-Added).

In current UK heart failure guidelines (NICE NG106), ACE inhibitors remain first-line RAAS blockade.

ARBs such as Amias are recommended for patients who are intolerant of ACE inhibitors (typically due to cough) or in specific clinical scenarios guided by the heart failure specialist team.

Blood pressure targets

NICE recommends the following blood pressure targets for most adults:

• Clinic blood pressure: below 140/90 mmHg (below 150/90 mmHg in patients aged 80 and over).
• Ambulatory or home blood pressure: below 135/85 mmHg (below 145/85 mmHg in patients aged 80 and over).

Achieving these targets often requires a combination of lifestyle measures and pharmacological treatment.

I encourage all my patients to monitor their blood pressure at home using a validated automated device, as home readings provide a more accurate picture of day-to-day blood pressure than occasional clinic measurements.

Lifestyle measures alongside Amias

Medication is most effective when combined with healthy lifestyle habits. Evidence-based measures for blood pressure reduction include:

• Reducing salt intake: aim for less than 6 g of salt per day. This alone can lower systolic blood pressure by 4 to 5 mmHg.
• Regular physical activity: at least 150 minutes of moderate-intensity exercise per week.
• Maintaining a healthy weight: a BMI between 18.5 and 24.9 kg/m2.
• Moderating alcohol: stay within the Chief Medical Officers' guideline of no more than 14 units per week.
• Dietary approaches: the DASH diet (rich in fruits, vegetables, whole grains, and low-fat dairy) has robust evidence for blood pressure reduction.
• Stopping smoking: while smoking does not directly raise blood pressure in the long term, it markedly increases cardiovascular risk and cessation is essential for overall cardiovascular health.

Obtaining Amias in the United Kingdom

Amias is a prescription-only medicine available on the NHS.

The standard NHS prescription charge is £9.90 per item in England, with prescriptions free of charge in Scotland, Wales, and Northern Ireland.

Generic candesartan cilexetil is also available and is significantly less expensive than the branded product.

Your GP or hospital specialist will determine which formulation to prescribe based on local formulary guidance.

Many patients started on Amias may be switched to generic candesartan at their next prescription review.

Regular follow-up is important. After starting Amias, your GP will check your blood pressure, kidney function (eGFR and creatinine), and electrolytes (particularly potassium) within one to two weeks and then periodically thereafter.

Understanding blood pressure readings

Blood pressure is recorded as two numbers: systolic pressure (the pressure when the heart contracts) over diastolic pressure (the pressure when the heart relaxes between beats).

A reading of 120/80 mmHg is considered ideal.

Readings consistently above 140/90 mmHg in a clinic setting (or above 135/85 mmHg on home or ambulatory monitoring) are classified as hypertension.

Many patients are surprised to learn that blood pressure fluctuates throughout the day and can be affected by stress, exercise, caffeine, medication timing, and even the act of having it measured (so-called "white coat" hypertension).

This is why NICE recommends confirming a diagnosis of hypertension with ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) before starting lifelong treatment.

If you are prescribed Amias, home monitoring is a valuable way to track your response and ensure your treatment is working effectively.

The importance of medication adherence

Hypertension is often called a "silent condition" because it rarely causes symptoms until a serious complication occurs.

This means that many patients struggle with the concept of taking a daily tablet for something they cannot feel.

In my experience, the patients who do best are those who understand the long-term stakes: uncontrolled hypertension substantially increases the risk of stroke, heart attack, kidney failure, heart failure, and vascular dementia.

Taking Amias every day is an investment in future health, even if the immediate benefits are not visible.

Practical tips for remembering your medicine include linking it to a daily routine (such as brushing your teeth), using a pill organiser, or setting a daily phone alarm.

If you find that side effects are affecting your willingness to continue, discuss this with your GP, there are many antihypertensive options, and finding the right one for you is important.

Storage

• Store Amias tablets below 30 degrees Celsius.
• Keep in the original packaging to protect from moisture.
• Do not use after the expiry date on the blister or carton.
• Keep out of the sight and reach of children.

Frequently asked questions

What is the difference between Amias and ramipril?

Ramipril is an ACE inhibitor, while Amias (candesartan) is an ARB. Both reduce blood pressure by acting on the renin-angiotensin system, but they do so at different points.

ACE inhibitors block the formation of angiotensin II, while ARBs block its action at the receptor.

The main practical difference for patients is that ACE inhibitors more commonly cause a dry cough, which is a frequent reason for switching to an ARB like Amias.

Can I take Amias with other blood pressure medicines?

Yes, Amias is commonly combined with other antihypertensives, particularly calcium channel blockers (such as amlodipine) and thiazide-like diuretics (such as indapamide), in line with NICE guidance.

However, do not combine Amias with an ACE inhibitor or another ARB unless specifically instructed by a specialist, as dual RAAS blockade increases the risk of hyperkalaemia, renal impairment, and hypotension.

Will I need to take Amias for life?

In most cases, blood pressure treatment is long-term. Hypertension is usually a chronic condition, and stopping medication often leads to a return of elevated blood pressure.

However, some patients who achieve significant lifestyle improvements (weight loss, increased exercise, dietary changes) may be able to reduce or, in rare cases, discontinue their medication under medical supervision.

Can I drink alcohol while taking Amias?

Moderate alcohol consumption is generally acceptable, but alcohol can lower blood pressure and may enhance the blood pressure-lowering effect of Amias, potentially causing dizziness or lightheadedness. Stay within the recommended guidelines and be cautious when starting treatment.

Sources

• EMC, Electronic Medicines Compendium (SmPC for Amias)
• BNF, British National Formulary
• NICE NG136, Hypertension in adults
• NICE NG106, Chronic heart failure in adults
• NHS, High blood pressure
• British and Irish Hypertension Society